The immune system deploys a multitude of innate and adaptive mechanisms not only to
ward off pathogens but also to prevent malignant transformation (“immune surveillance”) …

Evidence of significant hearing loss during the early days of use of cisplatin as a
chemotherapeutic agent in cancer patients has stimulated research into the causes and …

Administration of cisplatin, a common chemotherapeutic drug, has an inevitable side effect
of sensorineural hearing loss. The main etiologies are stria vascularis injury, spiral ganglion …

Nuclear factor erythroid 2-related factor 2 (Nrf2) is a vital transcription factor and its induction
is of significant importance for protecting against oxidative damage. Increased levels of …

Hearing loss is a significant health problem that can result from a variety of exogenous
insults that generate oxidative stress and inflammation. This can produce cellular damage …

Cisplatin is a chemotherapeutic agent that is widely used to treat a variety of malignant
tumors. Serious dose-limiting side effects like ototoxicity, nephrotoxicity and neurotoxicity …

In our previous study, we clearly demonstrated the roles of pro-inflammatory cytokines,
including tumor necrosis factor-α, interleukin-1β (IL-1β), and IL-6, and subsequent reactive …

Cisplatin is widely used for the treatment of a number of solid malignant tumors. However,
ototoxicity induced by cisplatin is an obstacle to effective treatment of tumors. The basis for …

Cisplatin is a highly effective antineoplastic agent used to treat solid tumors. Unfortunately,
the administration of this drug leads to significant side effects, including ototoxicity …

Cisplatin is a platinum-based chemotherapeutic that has long since been effective against a
variety of solid-cancers, substantially improving the five-year survival rates for cancer …